Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Invivyd, Inc.
  6. News
  7. Summary
    IVVD   US00534A1025

INVIVYD, INC.

(IVVD)
  Report
Real-time Estimate Cboe BZX  -  11:05 2022-11-30 am EST
2.095 USD   -4.34%
11/17Invivyd Says it Teamed Up With Population Health Partners to Accelerate Clinical Development Projects
MT
11/17Invivyd, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

INVIVYD, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)

09/13/2022 | 07:32am EST

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal

           Year.


On September 9, 2022, Invivyd, Inc. (the "Company") filed a certificate of amendment (the "Certificate of Amendment") to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware solely to change the Company's name from "Adagio Therapeutics, Inc." to "Invivyd, Inc." The name change became effective on September 13, 2022. A copy of the Certificate of Amendment is attached as Exhibit 3.1 hereto and incorporated herein by reference.

In connection with the name change, the Company's Board of Directors amended the Company's Amended and Restated Bylaws (the "Bylaws") to reflect the Company's name change, also effective September 13, 2022. No other changes were made to the Bylaws. A copy of the Bylaws reflecting this amendment is attached as Exhibit 3.2 hereto and incorporated herein by reference.

The Company's common stock previously traded on the Nasdaq Global Market under the ticker symbol "ADGI" and, effective as of September 13, 2022, is trading on the Nasdaq Global Market under the new ticker symbol "IVVD."

The name change does not affect the rights of the Company's security holders, and the CUSIP number for the Company's common stock will continue to be 00534A102.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits

Exhibit
  No.       Description

 3.1          Certificate of Amendment to Amended and Restated Certificate of
            Incorporation

 3.2          Amended and Restated Bylaws

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about INVIVYD, INC.
11/17Invivyd Says it Teamed Up With Population Health Partners to Accelerate Clinical Develo..
MT
11/17Invivyd, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Se..
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
GL
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
AQ
11/17Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical De..
CI
11/10INVIVYD, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/10Transcript : Invivyd, Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10Invivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/10Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
GL
11/09Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
GL
More news
Analyst Recommendations on INVIVYD, INC.
More recommendations